Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2014/07010Aexternal-prioritypatent/TR201407010A2/tr
Application filed by Arven Ilac Sanayi Ve Ticaret AsfiledCriticalArven Ilac Sanayi Ve Ticaret As
Publication of MA39289ApublicationCriticalpatent/MA39289A/fr
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La présente invention se rapporte à une formulation pharmaceutique pour inhalation comprenant vilanterol en tant qu'agent actif, un excipient et du stéarate de magnésium dans le traitement et la prophylaxie des maladies respiratoires telles que l'asthme, la broncho-pneumopathie chronique obstructive (bpco), ainsi qu'à un procédé pour produire ce formulation.
MA039289A2014-06-162015-06-15Formulations pharmaceutiques de vilanterol
MA39289A
(fr)
composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
C38 UNDERSTANDING THERAPEUTICS IN IPF: Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres